TD Private Client Wealth LLC Sells 3,232 Shares of Veeva Systems Inc. $VEEV

TD Private Client Wealth LLC lowered its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 60.6% during the fourth quarter, Holdings Channel reports. The fund owned 2,101 shares of the technology company’s stock after selling 3,232 shares during the period. TD Private Client Wealth LLC’s holdings in Veeva Systems were worth $469,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of VEEV. Alphinity Investment Management Pty Ltd bought a new position in shares of Veeva Systems in the 3rd quarter valued at about $422,241,000. Durable Capital Partners LP acquired a new position in Veeva Systems in the second quarter valued at approximately $281,351,000. ABN AMRO Bank N.V. acquired a new position in Veeva Systems in the third quarter valued at approximately $246,625,000. AQR Capital Management LLC grew its holdings in Veeva Systems by 31.2% during the 3rd quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company’s stock worth $706,078,000 after acquiring an additional 574,164 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Veeva Systems by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 15,429,231 shares of the technology company’s stock worth $4,596,522,000 after acquiring an additional 457,806 shares during the period. Institutional investors own 88.20% of the company’s stock.

Veeva Systems Price Performance

Shares of NYSE:VEEV opened at $158.24 on Friday. The company has a market capitalization of $25.84 billion, a price-to-earnings ratio of 29.25, a P/E/G ratio of 0.74 and a beta of 0.92. The firm’s 50 day simple moving average is $168.92 and its 200 day simple moving average is $204.64. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $310.50.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings results on Wednesday, March 4th. The technology company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $835.95 million for the quarter, compared to the consensus estimate of $810.95 million. Veeva Systems had a net margin of 28.44% and a return on equity of 13.80%. Veeva Systems’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period last year, the company posted $1.74 EPS. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. Equities research analysts expect that Veeva Systems Inc. will post 6.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

VEEV has been the subject of a number of analyst reports. Zacks Research lowered shares of Veeva Systems from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. William Blair reaffirmed an “outperform” rating on shares of Veeva Systems in a report on Tuesday, March 10th. Morgan Stanley lifted their target price on shares of Veeva Systems from $205.00 to $215.00 and gave the stock an “equal weight” rating in a report on Thursday, March 5th. Wall Street Zen lowered shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Finally, Wells Fargo & Company lowered their target price on shares of Veeva Systems from $333.00 to $317.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Veeva Systems currently has an average rating of “Moderate Buy” and an average target price of $276.52.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: One Seeking Alpha article argues that AI fears around Veeva Systems (VEEV) are overdone and says the recent selloff may be creating an opportunity for investors. Veeva Systems: AI Fears Look Overdone, The Selloff Creates An Opportunity
• Positive Sentiment: Analyst-oriented coverage continues to frame Veeva as a strong growth stock, with Wall Street sentiment described as optimistic and the company still viewed favorably on a growth basis. Here’s Why Veeva Systems (VEEV) is a Strong Growth Stock
• Positive Sentiment: Another article highlights RTSM momentum as a longer-term growth driver, saying Veeva is winning business with major pharma customers and strengthening its clinical software strategy. Veeva Systems’ RTSM Momentum Signals Another Long-Term Growth Driver
• Positive Sentiment: Multiple pieces note that brokerage coverage remains broadly constructive, with an average recommendation equivalent to a Buy, and one article cites Michael Burry’s reported interest in the stock as a sentiment boost. Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Recent market recap pieces simply note that Veeva has been trading below the broader market, which reflects sentiment rather than a new company-specific catalyst. Veeva Systems (VEEV) Stock Slides as Market Rises: Facts to Know Before You Trade

Insider Buying and Selling

In other Veeva Systems news, Director Priscilla Hung sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $155.64, for a total transaction of $116,730.00. Following the sale, the director directly owned 3,253 shares in the company, valued at approximately $506,296.92. This trade represents a 18.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.60% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.